Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 18, Issue 8, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-016-0604-3
Keywords
Statin myalgia; Myopathy; Creatine kinase
Categories
Funding
- Regeneron Pharmaceuticals, Inc.
- Genomas
- Roche
- Sanofi
- Regeneron
- Esperion
- Amarin
- Pfizer
Ask authors/readers for more resources
Purpose of Review To review the interactions between statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition. Recent Findings Statins are highly effective for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD). However, statins also raise levels of PCSK9, a protein that increases circulating LDL-C levels by increasing LDL-C receptor degradation. Increases in PCSK9 levels also reduce the LDL-C response to statin therapy. Summary The interactions between statins, PCSK9, LDL-C, and cardiovascular risk are multifaceted and are influenced by genetic, lifestyle, and environmental factors as well as lipid-lowering therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available